1
|
Chaoui M, Fischer E, Perinel-Ragey S, Prévôt N, Leclerc L, Pourchez J. Development of a Novel Bronchodilator Vaping Drug Delivery System Based on Thermal Degradation Properties. Pharmaceuticals (Basel) 2023; 16:1730. [PMID: 38139856 PMCID: PMC10747077 DOI: 10.3390/ph16121730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 12/07/2023] [Accepted: 12/13/2023] [Indexed: 12/24/2023] Open
Abstract
This work aims to investigate bronchodilator delivery with the use of different vaping drug delivery systems (VDDS) by determining the dose equivalence delivered in relation to different references: a clinical jet nebulizer, a pMDI (pressurized metered dose inhaler) and a DPI (dry powder inhaler). Three different bronchodilators were used (terbutaline, salbutamol hemisulfate, ipratropium bromide). The e-liquids contained the active pharmaceutical ingredient (API) in powder form. Two different VDDS were tested (JUUL and a GS AIR 2 atomizer paired with a variable lithium-ion battery (i-stick TC 40 W), 1.5 ohm resistance, and 15 W power). Samples were collected using a glass twin impinger (GTI). High-performance liquid chromatography (HPLC) was used to quantify the drugs. A next-generation impactor (NGI) was used to measure the particle size distribution. Terbutaline emerged as the optimal API for bronchodilator delivery in both VDDS devices. It achieved the delivery of a respirable dose of 20.05 ± 4.2 µg/puff for GS AIR 2 and 2.98 ± 0.52 µg/puff for JUUL. With these delivered doses, it is possible to achieve a dose equivalence similar to that of a jet nebulizer and DPI, all while maintaining a reasonable duration, particularly with the GS AIR 2. This study is the first to provide evidence that vaping bronchodilators work only with appropriate formulation, vaping technology, and specific drugs, depending on their thermal degradation properties.
Collapse
Affiliation(s)
- Mariam Chaoui
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
| | - Emmanuelle Fischer
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
| | - Sophie Perinel-Ragey
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
- Medical-Surgical Intensive Care Unit, CHU Saint-Etienne, F-42055 Saint-Etienne, France
| | - Nathalie Prévôt
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
- Nuclear Medicine Unit, CHU Saint-Etienne, F-42055 Saint-Etienne, France
| | - Lara Leclerc
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
| | - Jérémie Pourchez
- Mines Saint-Etienne, Université Jean Monnet Saint-Etienne, INSERM, Sainbiose U1059, Centre CIS, F-42023 Saint-Etienne, France; (M.C.); (E.F.); (S.P.-R.); (N.P.); (L.L.)
| |
Collapse
|
2
|
Abstract
Current guidelines recommend inhaled pharmacologic therapy as the preferred route of administration for treating COPD. Bronchodilators (β2-agonists and antimuscarinics) are the mainstay of pharmacologic therapy in patients with COPD, with long-acting agents recommended for patients with moderate to severe symptoms or those who are at a higher risk for COPD exacerbations. Dry powder inhalers and pressurized metered dose inhalers are the most commonly used drug delivery devices, but they may be inadequate in various clinical scenarios (eg, the elderly, the cognitively impaired, and hospitalized patients). As more drugs become available in solution formulations, patients with COPD and their caregivers are becoming increasingly satisfied with nebulized drug delivery, which provides benefits similar to drugs delivered by handheld inhalers in both symptom relief and improved quality of life. This article reviews recent innovations in nebulized drug delivery and the important role of nebulized therapy in the treatment of COPD.
Collapse
Affiliation(s)
- Donald P Tashkin
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| |
Collapse
|
3
|
Pulmonary Drug Delivery. Drug Deliv 2016. [DOI: 10.1201/9781315382579-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
4
|
Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv 2016; 13:1559-1571. [PMID: 27267298 DOI: 10.1080/17425247.2016.1198774] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Inhalation therapy is a convenient method of treating respiratory diseases. The key factors required for inhalation are the preparation of drug carriers (aerosol particles) allowing reproducible dosing during administration. These technical challenges are accomplished with a variety of inhalation devices (inhalers) and medicinal formulations, which are optimized to be easily converted into inhalable aerosols. Areas covered: This review is focused on the most important, but often overlooked, effects, which are required for the reliable and reproducible inhalable drug administration. The effects of patient-related issues that influence inhalation therapy, such as proper selection of inhalers for specific cases is discussed. We also discuss factors that are the most essential if generic inhalation product should be considered equivalent to the drugs with the clinically confirmed efficacy. Expert opinion: Proper device selection is crucial in clinical results of inhalation therapy. The patients' ability to coordinate inhalation with actuation, generation of optimal flow through the device, use of optimal inspiratory volume, all produces crucial effects on disease control. Also the severity of the disease process effects proper use of inhalers. Interchanging of inhalers can produce potentially conflicting problem regarding efficacy and safety of inhalation therapy.
Collapse
Affiliation(s)
- Michal Pirozynski
- a Allergy and Pulmonology Department , Postgraduate Center for Medical Education , Warsaw , Poland
| | - Tomasz R Sosnowski
- b Faculty of Chemical and Process Engineering , Warsaw University of Technology , Warsaw , Poland
| |
Collapse
|
5
|
Stein SW, Sheth P, Younis US, Mogalian E, Myrdal PB. Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs. Mol Pharm 2015; 12:3455-67. [DOI: 10.1021/acs.molpharmaceut.5b00467] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Stephen W. Stein
- 3M Drug Delivery Systems, 3M Center—Building
260-3A-05, St. Paul, Minnesota 55144, United States
| | - Poonam Sheth
- Cirrus Pharmaceuticals, Inc., 511 Davis Drive, Suite 100, PO Box 14748, Morrisville, North Carolina 27560, United States
| | - Usir S. Younis
- College
of Pharmacy, The University of Arizona, 1703 East Mabel Street, PO Box 210207, Tucson, Arizona 85721, United States
| | - Erik Mogalian
- Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States
| | - Paul B. Myrdal
- College
of Pharmacy, The University of Arizona, 1703 East Mabel Street, PO Box 210207, Tucson, Arizona 85721, United States
| |
Collapse
|
6
|
Morin CM, Ivey JW, Titosky JT, Suderman JD, Olfert JS, Vehring R, Finlay WH. Performance of Pressurized Metered‐Dose Inhalers at Extreme Temperature Conditions. J Pharm Sci 2014; 103:3553-3559. [DOI: 10.1002/jps.24145] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Revised: 08/01/2014] [Accepted: 08/11/2014] [Indexed: 11/07/2022]
|
7
|
Titosky JTF, Morin CMD, Suderman JD, Olfert JS, Finlay WH, Vehring R. The effect of altitude on inhaler performance. J Pharm Sci 2014; 103:2116-2124. [PMID: 24890630 DOI: 10.1002/jps.24032] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Revised: 05/01/2014] [Accepted: 05/09/2014] [Indexed: 11/05/2022]
Abstract
The purpose of the study is to understand the effect of altitude on the performance of selected pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs). A testing apparatus that created consistent breath profiles through the Alberta Idealized Throat was designed to test five pMDIs and two DPIs at altitudes of 670, 2450, 3260, and 4300 m. Both gravimetric and chemical assays were conducted to determine the in vitro lung dose. Additionally, spray duration and shot weight for pMDIs and device resistance for DPI were measured. There was no significant change in in vitro lung dose for any of the pMDIs tested. Shot weight and spray duration were unaffected. The device resistance of the DPIs decreased with increasing altitude and was successfully modeled as a function of ambient pressure. The in vitro lung dose of both DPIs showed no significant change when operated with an inhaler pressure drop of 4 kPa, but for the Bricanyl(®) Turbuhaler(®), a significant decrease occurred when matching the volumetric inspiratory flow rate to that of the baseline altitude.
Collapse
Affiliation(s)
- Jordan T F Titosky
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada
| | - Chelsea M D Morin
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada
| | - Jonathan D Suderman
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada
| | - Jason S Olfert
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada
| | - Warren H Finlay
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada
| | - Reinhard Vehring
- Department of Mechanical Engineering, University of Alberta, Edmonton, AlbertaT6G 2T8, Canada.
| |
Collapse
|
8
|
Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014; 15:434-55. [PMID: 24452499 DOI: 10.1208/s12249-013-0063-x] [Citation(s) in RCA: 101] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 11/15/2013] [Indexed: 12/20/2022] Open
Abstract
Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.
Collapse
|
9
|
Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014. [PMID: 24452499 DOI: 10.1208/s12249-013-0063-x.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.
Collapse
Affiliation(s)
- Paul B Myrdal
- College of Pharmacy, University of Arizona, 1703 E. Mabel St., PO Box 210207, Tucson, Arizona, 85721, USA,
| | | | | |
Collapse
|
10
|
Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration. Eur J Pharm Biopharm 2014; 86:115-9. [DOI: 10.1016/j.ejpb.2013.09.006] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 09/03/2013] [Accepted: 09/09/2013] [Indexed: 11/18/2022]
|
11
|
Inhalation toxicity of soman vapor in non-anesthetized rats: A preliminary assessment of inhaled bronchodilator or steroid therapy. Chem Biol Interact 2013; 206:452-61. [DOI: 10.1016/j.cbi.2013.07.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Revised: 07/09/2013] [Accepted: 07/12/2013] [Indexed: 11/19/2022]
|